



Khapzory™ (levoleucovorin) – New Drug Approval

- On October 23, 2018, [Spectrum announced](#) the [FDA approval](#) of [Khapzory \(levoleucovorin\)](#) injection for rescue after high-dose [methotrexate](#) therapy in patients with osteosarcoma, diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination, and for the treatment of patients with metastatic colorectal cancer in combination with [fluorouracil](#).
 - Khapzory is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 because of the risk of progression of neurologic manifestations despite hematologic remission.
- Levoleucovorin is available [generically](#) and as brand [Fusilev®](#).
- The efficacy and safety of Khapzory is based on prior clinical studies evaluating levoleucovorin as rescue therapy after high-dose methotrexate in patients with osteosarcoma and in patients with metastatic colorectal cancer.
- Khapzory is contraindicated in patients who have had severe hypersensitivity to leucovorin products, [folic acid](#), or [folinic acid](#).
- Warnings and precautions of Khapzory include increased gastrointestinal toxicities with fluorouracil and drug interaction with [trimethoprim-sulfamethoxazole](#).
- The most common adverse reactions ($\geq 20\%$) with levoleucovorin use in patients receiving high dose methotrexate therapy with levoleucovorin rescue were stomatitis and vomiting.
- The most common adverse reactions ($> 50\%$) with levoleucovorin use in patients receiving levoleucovorin in combination with fluorouracil for metastatic colorectal cancer were stomatitis, diarrhea, and nausea.
- The recommended dose of Khapzory should be given by intravenous administration only. Do not administer intrathecally.
 - Refer to the Khapzory prescribing information for dosing instructions for all indications.
- Spectrum plans to launch Khapzory in January 2019. Khapzory will be available as a 175 mg and 300 mg single-dose vial.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.